Somani
Hospital was established on February 1st, 2007 by Dr. Rajkumari
Somani.DIRECTOR: DR. RAJKUMARI SOMANI
Dr. (Mrs.) Rajkumari Somani has completed her graduation
and post graduation from Shri Ramchandra Medical College, Chennai (Deemed
University). It was her dedication and devotion in the field of Obst. and
Gynaecology that she established a fully dedicated and developed 20 beded
hospital with all modern and state of the art medical and surgical facilities.
She has established full Laparoscopic / Hysteroscopy Gynecology surgery
facilities. She regularly doing Colposcopy.
![](/Data/SummerNoteImage/d0b9c0f1-6b94-48c6-9310-00b4c78debc1.jpg)
ONGOING TRAIL
Ref: E7080-M091-511: “A Prospective,
Multicentre, Post-Marketing Phase IV Study to Assess the safety and Efficacy of
Lenvatinib as First-Line Treatment in Patients with Unresectable Hepatocellular
Carcinoma (HCC)” Site: Somani Hospital, Principal Investigator - Dr. Naresh
SomaniRef: Protocol: 0063-17 A global, multicenter, three arms, open-label
randomized study to evaluate the e?cacy and safety of Nanosomal Docetaxel Lipid
Suspension compared to Taxotere® (Docetaxel Injection Concentrate) in
triple-negative breast cancer patients with locally advanced or metastatic
breast cancer after failure to prior chemotherapy.Protocol Title :‘A
Prospective, Randomized, Multicentre, Comparative, open-label, Parallel study
to evaluate the E?cacy, Safety and Pharmacokinetics of Test-Trastuzumab
Emtansine (ZRC-3255; Cadila Healthcare Ltd) and Reference-Trastuzumab Emtansine
(Kadcyla@, a product of Roche) in HER2- Positive Metastatic Breast Cancer
PatientsProtocol Title: A randomized, double-blind, placebo-controlled, phase III
study evaluating the e?cacy and safety of pembrolizumab plus platinum-based
doublet chemotherapy with or without canakinumab as ?rst line therapy for
locally advanced or metastatic non-squamous and squamous non-small cell lung
cancer subjects (CANOPY-1).Protocol Title: “A pilot study (Phase II Trial )of
Ge?tinib With Pemetrexed as First-Line Therapy in Patients With Advanced
Non-squamous Non–Small-Cell Lung Cancer With Activating Epidermal Growth Factor
Receptor Mutations positive patients.” (Investigator Initiative Trial)Protocol
Number: WOC/AMS/CT-44/14 “Asurveillance study on the antibiotic susceptibility
pattern of bacterial isolates collected from patients at various Indian
tertiary care hospitals”
![](/Data/SummerNoteImage/ef2654b3-c7a1-492a-aaa0-823033a69e5b.jpg)
INVESTIGATOR INITIATIVE
CLINICAL TRIAL
A pilot study (Phase II Trial) of
Cetuximab with Afatinib as First-Line Therapy in patients With Advanced
Non-Sequamous Non-Samall-Cell Lung Cancer With Activating Epidermal Growth
Factor Receptor Multations positive patients. - PI Dr. Naresh SomaniA pilot
study (Phase II Trial ) of Gefitinib/Afatinib with pemetrexed as First-Line
therapy in Patients with advanced Non-squamous Non-Small-Cell Lung Cancer with
Activating Epidermal Growth Factor Receptor Mutations positive patients. PI Dr.
Naresh SomaniA pilot study (Phase II Trial ) of Nivolumab with Pemetrexed as
Palliative Chemotherapy in Patients with advanced Non-Small-Cell Lung Cancer
with Activating Epidermal Growth Factor Receptor Mutations positive patients.
PI Dr. Naresh Somani
COMPLETED TRAIL
Protocol No. CA209-887: Study Title:
Clinical Outcomes of CLL and MCL patients treated with Ibrutinib : An
observational retrospective medical chart review from India - (Recruitment
Ongoing) - Dr. Naresh Somani